The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran.
Ahmed Shawky ElserafyAhmed BendaryAtef ElbahryElsayed FaragTamer MostafaOsama SanadAhmed ElkershMohammed SelimHany RagyHazem KhamisWaleed AbdoAshraf RedaPublished in: Cardiology and therapy (2022)
The Egyptian Association for Vascular Biology and Atherosclerosis (EAVA) analyzed the data necessary for obtaining clear indications for the usage of inclisiran. We propose the addition of inclisiran to statins with or without ezetimibe for patients with documented atherosclerotic cardiovascular disease (ASCVD) or similar risk, familial hypercholesterolemia (FH) with another major risk factor, and very high and high risk diabetes mellitus, who did not reach LDL-c goals and/or with true statin intolerance. Inclisiran is also recommended as upfront therapy, with triple combination, in extreme risk subjects such as those with post acute coronary syndromes (ACS).
Keyphrases
- cardiovascular disease
- acute coronary syndrome
- risk factors
- type diabetes
- cardiovascular events
- coronary artery disease
- cardiovascular risk factors
- public health
- electronic health record
- stem cells
- skeletal muscle
- adipose tissue
- insulin resistance
- machine learning
- artificial intelligence
- mesenchymal stem cells
- low density lipoprotein